Speaker

Dr. Hui Tian is the founder and CEO of Axbio, a global leader in integrated circuit biotechnology. Axbio is developing a next-generation electrochemical detection platform to transform the life sciences tools and diagnostics industry.
Dr. Tian is a leading scientist who is the inventor of over 100 granted patents globally, with extensive leadership in biotechnology. Before founding Axbio, Dr. Tian was Vice President at a California-based company which develops genetic analysis platform designed for real-time DNA sequencing, and later continued as Vice President at the sequencing division of a global pharmaceutical company until 2016. Dr. Tian also served leadership roles at Silicon Valley technology companies, including vice president at InVisage Technologies Inc., director at Pixim, Inc., and principal sensor scientist of IC Media Corporation. He received his PhD & MS from Stanford University and MS & BS from Tsinghua University (China).

Dr. Wenzhi Tian, is a renowned expert in cancer immunotherapies with over 30 years of academic and industrial experience in the field of immuno-oncology. Dr. Wenzhi Tian is the Founder, Chairman and Chief Executive Officer of ImmuneOnco Biopharma. Prior to founding our Company in 2015, Dr. Tian co-founded and managed Huabo Biopharm and served as the principal research scientist at ImClone Systems. Before devoting himself to the pharmaceutical industry, Dr. Tian spent close to 15 years conducting academic research specifically on immunology at various research institutes, including Karolinska Institute in Sweden, Weill Medical College of Cornell University and North Shore University Hospital in the United States. With extensive expertise in cancer immunology, Dr. Tian taught as adjunct professor at Fudan University, Zhengzhou University and Henan University. Based on his in- depth understanding of cancer immunology, Dr. Tian has been at the forefront of scientific research and built a proven track record in target validation, molecule design and drug development for innovative immunotherapies. He identified CD47 as a promising immunotherapeutic target and commenced drug research on CD47 starting from 2010, roughly 10 years earlier than the validation of CD47 by clinical data. His deep expertise and foresight in target selection led to our development of multiple monoclonal antibody and bispecific molecules targeting CD24, another promising checkpoint since 2019, all with global first-in-class potential. A prolific scientist, Dr. Tian invented 28 issued patents and 44 patent applications, and published over 30 scientific papers in the area of immunology and CD47 in internationally-recognized journals.

Olga N. Tkacheva, MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Russian Clinical Research Center for Gerontology, an independent structural unit of the Pirogov Russian National Research Medical University under the Ministry of Health of the Russian Federation, Head of the Department of Age-Associated Diseases at the Faculty of Continuing Professional Education of Pirogov Russian National Research Medical University, and Chief Specialist on Gerontology of the Ministry of Health of the Russian Federation.
Olga N. Tkacheva is the author of more than 833 published works, including 763 articles in journals indexed in international databases and four patents for inventions. Olga N. Tkacheva is the author of the first National Handbook of Geriatrics and 22 monographs. Under Olga N. Tkacheva’s supervision, 25 candidates of medical sciences (PhD) and seven doctors of medical sciences (DSc) have been trained.
Olga N. Tkacheva is the Chair of the Dissertation Council at the Pirogov Russian National Research Medical University under the Ministry of Health of the Russian Federation, specializing in Gerontology and Geriatrics (Medical Sciences).
Olga N. Tkacheva’s recent research interests are devoted to mechanisms and patterns of the heart and blood vessels’ aging processes and their association with cellular replicative aging, problems of age-related metabolic disorders, prevention and treatment of age-associated diseases, and geriatric syndromes.

Professor Cheng-Hock Toh is Professor at the University of Liverpool and Consultant Haematologist at the Liverpool University Hospitals NHS Foundation Trust. He is Chair of the National Blood Transfusion Committee in England, and distinguished past positions include being the Academic Vice-President of the Royal College of Physicians (London), President of the British Society for Haematology (BSH) and National Haematology Lead of the National Institute of Health Research (NIHR) Clinical Research Network. He has received Achievement awards from the Royal College of Pathologists, European Society of Hematology and the BSH. His translational research programme on understanding blood changes during infection is world-leading, and he has published in the top journals in medicine, critical care and haematology. He holds several patents related to haemostatic dysfunction in critical illness. For services to haematology and medicine, he was appointed as Commander of the British Empire (CBE) by the late Queen Elizabeth II in 2022.

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. He completed his International Baccalaureate on a United World College scholarship to Lester Pearson College, British Columbia, Canada. Dr Toh then obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr. Toh is an alumnus of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. Dr Toh received the National Senior Clinician Scientist Award in 2017, the National Medical Excellence Award (NMEA) in 2018, and the NMRC STaR Award in 2022.
Dr Toh is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS).
He is a member of the European Society for Medical Oncology (ESMO) Scientific Faculty for Cancer Immunology & Immunotherapy and chair of Investigational Immunotherapy at the ESMO Annual Congress 2026 in Madrid, Spain. Dr Toh has published over 160 peer-reviewed journal papers, including in The Lancet, The Lancet Oncology, The Lancet Gastroenterology & Hepatology, New England Journal of Medicine, Annals of Oncology, Nature Medicine, Nature Genetics, Nature Communications, Journal of Hepatology, etc.
Dr Toh is co-founder of NeoTILa Pte Ltd and won first prize (Global Health) at the Wolfson Entrepreneurship Competition, Cambridge University, in 2024.

Amber Tong is a reporter at Bloomberg News covering Chinese and Asian biotech and pharma companies – and the growing role they play on the global stage. She has written extensively about the aspirations and challenges of China’s innovative drugmakers, the evolution of the complex Chinese healthcare market and the dynamic relationship between China and multinational pharmaceutical giants. A trusted voice in the sector, her work has been cited by industry insiders and media publications. Previously, Amber was a senior editor at Endpoints News.

Zhou Tong’s research focuses on the mechanism of broad-spectrum antibody generation and in vitro antibody engineering. He established a microbial surface antibody display and screening platform based on phages, yeasts, and bacteria, and further integrating microfluidic systems, developed a high-throughput protein genotyping and rapid functional labeling system via microdroplet reactions, enabling high-throughput screening of multi-species antibody libraries and solving the microbial antibody display system’s low reproducibility. He co-founded a rare antibody discovery platform based on the “human distant-source immune animal model” with Ocean University of China, addressing the inability to generate antibodies against low-immunogenicity targets in humans and traditional mammalian models. He also collaborated with the National Microbial Data Center to build an antibody digital database (covering human, cotton rat, shark, etc.) and a modification hotspot prediction algorithm system, and further developed an AI-assisted antibody interpretation and prediction system based on antibody generation rules. These platforms strongly supported monoclonal identification and reshaping of multiple detection/therapeutic antibodies. He has co-authored 27 SCI papers, with 6 published as first/corresponding author in PNAS, Cell Reports, Nature Communications, and Nucleic Acids Research in recent five years, and holds 18 authorized national invention patents. His “Dia-19 bispecific antibody” for broad-spectrum COVID-19 prevention obtained national clinical trial approval in February 2024 (2024LP00386).

Gergely Tóth, PhD, MBA, is the CEO, CSO, and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease-modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech. Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S. and later was a Wellcome Trust-funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer’s and Parkinson’s disease. His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum’s ‘Top 10 Emerging Technologies 2019.

Prof. Tse Hung-Fat, MBBS, MD, PhD, FACC, FRCP, FESC Prof. Hung-Fat Tse is Chair Professor of Cardiovascular Medicine, and William MW Mong Professor in Cardiology; Chairpersons and Chief of Service of the Department of Medicine; Chief in the Cardiology Division, Department of Medicine, Queen Mary Hospital; Co director, Cardiac & Vascular Center, The University of Hong Kong – Shenzhen Hospital. He is also the academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong. He is a clinician scientist and an international expert in cardiovascular medicine, including cardiac pacing, clinical electrophysiology, and cardiovascular regeneration. Prof. Tse is one of the pioneers for novel therapies, including stem cell and devices for treatment of cardiovascular diseases. He has established the large animal laboratory for cardiovascular research as well the “Good Manufacturing Practice” laboratory for human stem cells and biological therapies in the University of Hong Kong. He has been awarded multiple major local grants (including the Theme Based Research Grant, Research Impact Fund and Innohealth) as well as national research grants (National Natural Science Foundation of China and 973 grants) for his researches. He has been participated into many international and regional clinical trials and studies, and is currently the Associate Editors for several international journals, including Cardiovascular Diabetology, Frontier in Cardiovascular Medicine, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology and Journal of Arrhythmia. He has published over 730 scientific publications in international top-ranking scientific journals, including New England Journal of Medicine, Lancet, Nature Medicine, Nature Cell Biology, Nature Genetic, Nature Protocol, Nature Communication, Nature Biomedical Engineering, Nature Disease Primer, Cell Stem Cell, Circulation, Journal of American College of Cardiology, and European Heart Journal.

Mr. Tse Hsin, aged 55, is an executive director, a member of the executive board committee and a senior vice president of the Company. Mr. Tse Hsin is mainly responsible for mergers and acquisitions and financing activities of the Group. Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor’s Degree (Honors) in Industrial Engineering. He joined the Group in August 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd. Mr. Tse Hsin was a council member of the first council and an executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He was also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, a vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, an executive member of the third committee of the Shaanxi Cancer Fighting Association and a vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee. He was awarded the “Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province” by the Shaanxi Provincial Government and the “Outstanding entrepreneur who cares about his staff” by the Shaanxi Foreign Invested Enterprises Association. Mr. Tse Hsin was a director of CT Tianqing, Beijing Tide, and CP Pharmaceutical (Qingdao) Co., Ltd., and is currently a director of NJCTTQ， HanchorBio Inc. and CP Boai Investment Ltd., the chairman of Chia Tai Shaoyang Orthopedic Hospital, and a supervisor of CT Tianqing.